Cancer Moonshot

Cancer Moonshot. The Cancer Moonshot is a United States National Cancer Institute-led initiative aimed at accelerating cancer research, launched by Barack Obama in 2016, with Joe Biden as its chair. This initiative was inspired by the Apollo 11 moon landing and the Human Genome Project, and it involves collaboration between National Institutes of Health, Food and Drug Administration, Centers for Disease Control and Prevention, and other organizations, including American Cancer Society, American Association for Cancer Research, and Lance Armstrong Foundation. The initiative also involves partnerships with Google, IBM, and Microsoft to leverage their expertise in artificial intelligence, machine learning, and data analytics.

Background and launch

The Cancer Moonshot was launched in 2016, during the presidency of Barack Obama, with the goal of making a decade's worth of progress in cancer research in just five years. The initiative was led by Joe Biden, who had lost his son Beau Biden to glioblastoma in 2015. The launch of the initiative was supported by National Cancer Institute director Harold Varmus, National Institutes of Health director Francis Collins, and other prominent cancer researchers, including James Allison, Jennifer Doudna, and Elizabeth Blackburn. The initiative also received support from American Cancer Society CEO Gary Reedy, American Association for Cancer Research president Nancy Davidson, and Lance Armstrong Foundation founder Lance Armstrong.

Goals and initiatives

The Cancer Moonshot has several key goals, including improving our understanding of cancer biology, developing new cancer treatments, and improving cancer prevention and early detection. The initiative involves a range of research projects, including studies of immunotherapy, genomics, and epigenetics, and it involves collaboration between researchers at National Institutes of Health, Stanford University, Harvard University, and other institutions. The initiative also involves partnerships with pharmaceutical companies, including Pfizer, Merck, and Bristol-Myers Squibb, to accelerate the development of new cancer treatments. Additionally, the initiative involves collaboration with patient advocacy groups, including American Cancer Society, Cancer Research Institute, and Leukemia & Lymphoma Society, to ensure that the needs and perspectives of cancer patients are taken into account.

Progress and achievements

The Cancer Moonshot has made significant progress since its launch, with major advances in our understanding of cancer biology and the development of new cancer treatments. For example, researchers at National Institutes of Health and University of Texas MD Anderson Cancer Center have made important discoveries about the role of immunotherapy in cancer treatment, and researchers at Stanford University and Massachusetts Institute of Technology have developed new genomic and epigenetic tools for cancer research. The initiative has also led to the development of new cancer treatments, including pembrolizumab and nivolumab, which have been approved by the Food and Drug Administration for the treatment of melanoma and other types of cancer. Furthermore, the initiative has involved collaboration with World Health Organization, European Organisation for Research and Treatment of Cancer, and International Agency for Research on Cancer to advance global cancer research.

Funding and budget

The Cancer Moonshot has received significant funding from the United States Congress, with an initial investment of $1 billion in 2016. The initiative has also received funding from private foundations, including the Bill and Melinda Gates Foundation, Gordon and Betty Moore Foundation, and Lasker Foundation. The budget for the initiative includes funding for research grants, clinical trials, and infrastructure development, and it involves collaboration between National Institutes of Health, National Cancer Institute, and other organizations to ensure that resources are allocated effectively. Additionally, the initiative has involved partnerships with Google.org, Microsoft Research, and IBM Watson Health to leverage their expertise in data analytics and artificial intelligence.

Criticism and challenges

The Cancer Moonshot has faced criticism and challenges since its launch, including concerns about the pace of progress and the allocation of resources. Some critics, including Vincent DeVita, Samuel Broder, and Bernard Fisher, have argued that the initiative is too focused on basic research and not enough on translational research and clinical trials. Others, including Otis Brawley and Clifton Leaf, have raised concerns about the lack of diversity in the initiative's leadership and the need for greater involvement of patient advocacy groups. Despite these challenges, the initiative has made significant progress and has the potential to make a major impact on cancer research and treatment, with support from National Academy of Sciences, Institute of Medicine, and American Association for the Advancement of Science.

Future directions

The Cancer Moonshot is expected to continue to play a major role in cancer research in the coming years, with a focus on accelerating the development of new cancer treatments and improving cancer prevention and early detection. The initiative will involve continued collaboration between researchers at National Institutes of Health, Stanford University, Harvard University, and other institutions, as well as partnerships with pharmaceutical companies, patient advocacy groups, and private foundations. The initiative will also involve the use of artificial intelligence, machine learning, and data analytics to accelerate cancer research and improve patient outcomes, with support from National Science Foundation, Department of Energy, and National Institute of Standards and Technology. Additionally, the initiative will involve international collaboration with European Union, World Health Organization, and International Union Against Cancer to advance global cancer research. Category:Cancer research initiatives